144 related articles for article (PubMed ID: 7533152)
1. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59.
Hüsler T; Lockert DH; Kaufman KM; Sodetz JM; Sims PJ
J Biol Chem; 1995 Feb; 270(8):3483-6. PubMed ID: 7533152
[TBL] [Abstract][Full Text] [Related]
2. Identity of the segment of human complement C8 recognized by complement regulatory protein CD59.
Lockert DH; Kaufman KM; Chang CP; Hüsler T; Sodetz JM; Sims PJ
J Biol Chem; 1995 Aug; 270(34):19723-8. PubMed ID: 7544344
[TBL] [Abstract][Full Text] [Related]
3. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
Husler T; Lockert DH; Sims PJ
Biochemistry; 1996 Mar; 35(10):3263-9. PubMed ID: 8605162
[TBL] [Abstract][Full Text] [Related]
4. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
5. Identity of the residues responsible for the species-restricted complement inhibitory function of human CD59.
Zhao XJ; Zhao J; Zhou Q; Sims PJ
J Biol Chem; 1998 Apr; 273(17):10665-71. PubMed ID: 9553129
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
7. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
[TBL] [Abstract][Full Text] [Related]
8. The human complement regulatory protein CD59 binds to the alpha-chain of C8 and to the "b"domain of C9.
Ninomiya H; Sims PJ
J Biol Chem; 1992 Jul; 267(19):13675-80. PubMed ID: 1377690
[TBL] [Abstract][Full Text] [Related]
9. Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.
Chang CP; Hüsler T; Zhao J; Wiedmer T; Sims PJ
J Biol Chem; 1994 Oct; 269(42):26424-30. PubMed ID: 7523406
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity.
Ninomiya H; Stewart BH; Rollins SA; Zhao J; Bothwell AL; Sims PJ
J Biol Chem; 1992 Apr; 267(12):8404-10. PubMed ID: 1373727
[TBL] [Abstract][Full Text] [Related]
11. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
12. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
Lehto T; Meri S
J Immunol; 1993 Nov; 151(9):4941-9. PubMed ID: 7691959
[TBL] [Abstract][Full Text] [Related]
13. Chimeric horse/human recombinant C9 proteins identify the amino acid sequence in horse C9 responsible for restriction of hemolysis.
Tomlinson S; Wang Y; Ueda E; Esser AF
J Immunol; 1995 Jul; 155(1):436-44. PubMed ID: 7541424
[TBL] [Abstract][Full Text] [Related]
14. Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins.
Koski CL; Estep AE; Sawant-Mane S; Shin ML; Highbarger L; Hansch GM
J Neurochem; 1996 Jan; 66(1):303-12. PubMed ID: 8522968
[TBL] [Abstract][Full Text] [Related]
15. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.
Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F
J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580
[TBL] [Abstract][Full Text] [Related]
16. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.
Farkas I; Baranyi L; Ishikawa Y; Okada N; Bohata C; Budai D; Fukuda A; Imai M; Okada H
J Physiol; 2002 Mar; 539(Pt 2):537-45. PubMed ID: 11882685
[TBL] [Abstract][Full Text] [Related]
17. Binding of human and rat CD59 to the terminal complement complexes.
Lehto T; Morgan BP; Meri S
Immunology; 1997 Jan; 90(1):121-8. PubMed ID: 9038722
[TBL] [Abstract][Full Text] [Related]
18. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
Meri S; Morgan BP; Davies A; Daniels RH; Olavesen MG; Waldmann H; Lachmann PJ
Immunology; 1990 Sep; 71(1):1-9. PubMed ID: 1698710
[TBL] [Abstract][Full Text] [Related]
19. Determination of the active site of CD59 with synthetic peptides.
Nakano Y; Tozaki T; Kikuta N; Tobe T; Oda E; Miura N; Sakamoto T; Tomita M
Mol Immunol; 1995 Mar; 32(4):241-7. PubMed ID: 7536892
[TBL] [Abstract][Full Text] [Related]
20. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
